TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Willingness to Participate in a HIV Vaccine Clinical Trial
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cardiac Syndrome X
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of rAAV9-DES-hGAA vector
Endpoint domain: Adverse events/effects
Primary endpoint: Consumption of morphine
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinical Response at the Test-of-Cure (TOC) Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to air leak closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of cluster-like attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of cephalic autonomic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnostic biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prognostic biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Tinnitus Functional Index (TFI) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to reactivation of cytomegalovirus (CMV) PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of patients reporting glare or haloes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 24 hour creatinine clearance (Single Dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 24 hour creatinine clearance (Multiple Dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from baseline in urine volume (Single Dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: neurosensory disturbancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PSS score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in the steady-state plasma pharmacokinetics of TMC435 following co-administration with erythromycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the steady-state plasma pharmacokinetics of TMC435 following co-administration with DRV/r
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent with glucose <40 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Uric Acid Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weight-for-length growth trajectory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Non-word Repetition (NWR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Phonological Training
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Working Memory (WM) training
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional plasticity of IL-17+ CD8 T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Biochemically validated abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in renal papillary density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Terminal Exponential Half-life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC(0-inf))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart failure rehospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: number of shocks recorded at 5 years after S-ICD implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of expulsion of the copper intrauterine device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Haemostatic Effectiveness of On-demand Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Haemostatic Effectiveness of Perioperative Prophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Bleeding Episodes During Follow-Up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor cell death estimated by percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ICIQ-B scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Base Excess
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of change in sputum log CFU/mL count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time Spent in Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time Spent in Sedentary Behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pterygium Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antiviral activity of PGDM1400
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cytokine Release Syndrome (CRS) Adverse Events Grade ≥ 3
Endpoint domain: Adverse events/effects
Primary endpoint: Neurotoxicity (NT) Adverse Events Grade ≥ 3
Endpoint domain: Adverse events/effects
Primary endpoint: Infection Adverse Events Grade ≥ 3
Endpoint domain: Adverse events/effects
Primary endpoint: Prolonged Grade ≥ 3 Cytopenia at Day 29
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in autism severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate in treating abdominal pain or discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Height-for-age z-score (HAZ) at 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validation of MDASI-GI Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: latencies and amplitudes between the brain and gut
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients achieving ASDAS<2.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost for primary hospital admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Visual prognosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient-Reported Outcomes (PRO) using WHO-5 item Well-being Index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent of infection strains which were also colonizer earlier
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of PD-0332334
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life of PD-0332334
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody response measured by HI test, MN test, SRH test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of the monovalent inactivated influenza vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Average systolic and average diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Visit-to-visit blood pressure variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Prostacyclin-associated Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Adverse Event Related to Injection Site Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Stunting reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Altered immune profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change From Baseline in Six Minutes Walk Distance (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve up to 24 hours (AUC0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mya Quality of Life 15 (Mya QoL15)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Myasthenia gravis Activities of daily living (MG ADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of suspected lesions positive by pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cardiorespiratory endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in knowledge, attitude and practice of primary healthcare physicians
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in Timed Up and Go (TUG) Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of Stay on Noninvasive Ventilation (NIV)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Identification of intra and extrahepatic hepatocellular carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: percent excess weight loss (EWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone mineral density of surrounding proximal femur
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuronal activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Headache Index Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent with interstitial blood glucose levels outside normal range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Distance Visual Acuity From Baseline in the Younger Cohort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence and severity of acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Systolic Blood Pressure at 1 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline in Diastolic Blood Pressure at 1 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Qualitative Changes in Dermal and Sub Dermal Collagen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Qualitative Changes in Dermal and Sub Dermal Vascularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change scores of Wechsler Memory Scale - Third Edition (WMS-III)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change scores of Wechsler Adult Intelligence Scale - Third Edition (WAIS-III)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change scores of Useful Field of View (UFOV)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change scores of Stroop Color-Word test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: kinematic gait parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in the maximum volume of O2 consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to bone marrow recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Composite Primary Endpoint of Cardiovascular Events
Endpoint domain: Mortality/survival
Primary endpoint: intestinal gas symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With CVC-Associated DVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of patients receiving intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Monocyte Platelet Aggregate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of time desaturated below 90% with combined oxygenation system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of time desaturated below 90% with single oxygenation system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of subjects with injection problems
Endpoint domain: Adverse events/effects
Primary endpoint: Composite Endpoint of MACCE
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of subjects with maximum diameter of induration ≥ 5mm in the tuberculin skin test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Amount of peri-implant bone level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reversal of growth arrest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone mineral density measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of CAD (coronary artery disease)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Infant Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of ulcerated limbs completely healed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diastolic function (Tei index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of SARS-CoV-2 positive persons
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Subpopulations of CD4, CD8, Th, Treg and B-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: postoperative pain score at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ischemic size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Treatment engagement rate
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change in EEG waveform amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Serial Reaction Time Task memory test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Paired Associates Learning memory test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Achieving target heart rate during treadmill exercise test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean number of alcohol drinks per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to cancer or high grade dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Anti Xa Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of BMS-986165
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Observed Plasma Concentration (Tmax) of BMS-986165
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under The Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) of BMS-986165
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-hospital Safety
Endpoint domain: Adverse events/effects
Primary endpoint: Specific airway resistance (sRAW kPa.L.s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of treatment successes and failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-1 specific CD4+ T helper cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HIV-1 specific CD8+ CTL responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Calcium Removal Out of Lumen Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Minimum Lumen Area Percent Stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Plaque Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain by visual analog scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oswestry disability Index (ODI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Development of acute graft-versus-host disease (GVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Growth of DWI lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Mean Bias
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for retreatment between the groups
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Loss of visual fields between the groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in dark adaptation between the groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with substantial angiographic reperfusion (mTICI) score of 2b/3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of failed procedures
Endpoint domain: Adverse events/effects
Primary endpoint: Change in sperm analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: International Hip Outcome Tool (IHOT-33)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Weight changes after 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: development of biliary complication
Endpoint domain: Adverse events/effects
Primary endpoint: Transfused red cell concentrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Platelet concentrates transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Systemic and Local Reactogenicity Rates
Endpoint domain: Adverse events/effects
Primary endpoint: FGF21 level in gingival crevicular fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achilles Tendon Length Measure (ATLM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Delayed post-polypectomy bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Discrimination of ADHD from non-ADHD users
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact on general intelligence index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mental workload scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: caecal intubation times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CK
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIF-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VEGF, VEGF 2, VEGF 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ang 1, Ang 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VCAM-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Amine Oxidase Copper-containing 3 (AOC3) Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pre or post-delivery nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Participants Who Had an Objective Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Borderline Personality Disorder symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area under the plasma drug concentration by time curve from time 0 to infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-1 RNA at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBV DNA at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Non-vellus Terminal Hair Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dental plaque/biofilm formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes